Literature DB >> 28767147

Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus.

Maria T Cencioni1, Roberta Magliozzi1,2, Richard Nicholas1,3, Rehiana Ali1,3, Omar Malik1,3, Richard Reynolds1, Giovanna Borsellino4, Luca Battistini4, Paolo A Muraro1,3.   

Abstract

Growing evidence points to a deregulated response to Epstein-Barr virus (EBV) in the central nervous system of patients with multiple sclerosis (MS) as a possible cause of disease. We have investigated the response of a subpopulation of effector CD8+ T cells to EBV in 36 healthy donors and in 35 patients with MS in active and inactive disease. We have measured the expression of markers of degranulation, the release of cytokines, cytotoxicity and the regulation of effector functions by inhibitory receptors, such as programmed death 1 (PD-1) and human inhibitor receptor immunoglobulin-like transcript 2 (ILT2). We demonstrate that polyfunctional cytotoxic CD8+ CD57+ T cells are able to kill EBV-infected cells in healthy donors. In contrast, an anergic exhaustion-like phenotype of CD8+ CD57+ T cells with high expression of PD-1 was observed in inactive patients with MS compared with active patients with MS or healthy donors. Detection of CD8+ CD57+ T cells in meningeal inflammatory infiltrates from post-mortem MS tissue confirmed the association of this cell phenotype with the disease pathological process. The overall results suggest that ineffective immune control of EBV in patietns with MS during remission may be one factor preceding and enabling the reactivation of the virus in the central nervous system and may cause exacerbation of the disease.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD8+ CD57+ T cells; Epstein-Barr virus; cytotoxic T-cell response; multiple sclerosis; programmed death 1

Mesh:

Substances:

Year:  2017        PMID: 28767147      PMCID: PMC5680058          DOI: 10.1111/imm.12808

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  68 in total

1.  Phenotypic characterization of autoreactive T cells in multiple sclerosis.

Authors:  Robert B Ratts; Nitin J Karandikar; Rehana Z Hussain; Judy Choy; Sara C Northrop; Amy E Lovett-Racke; Michael K Racke
Journal:  J Neuroimmunol       Date:  2006-08-08       Impact factor: 3.478

Review 2.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

3.  Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C.

Authors:  Simona Urbani; Carolina Boni; Gabriele Missale; Gianfranco Elia; Cristina Cavallo; Marco Massari; Giovanni Raimondo; Carlo Ferrari
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Authors:  Jan D Lünemann; Mar Tintoré; Brady Messmer; Till Strowig; Alex Rovira; Héctor Perkal; Estrella Caballero; Christian Münz; Xavier Montalban; Manuel Comabella
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Authors:  Nitin J Karandikar; Michael P Crawford; Xiao Yan; Robert B Ratts; Jason M Brenchley; David R Ambrozak; Amy E Lovett-Racke; Elliot M Frohman; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

7.  Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.

Authors:  George Makedonas; Natalie Hutnick; Danielle Haney; Alexandra C Amick; Jay Gardner; Gabriela Cosma; Adam R Hersperger; Douglas Dolfi; E John Wherry; Guido Ferrari; Michael R Betts
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

8.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

9.  Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.

Authors:  Samantha Jilek; Myriam Schluep; Pascal Meylan; François Vingerhoets; Laurence Guignard; Anita Monney; Joerg Kleeberg; Géraldine Le Goff; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Brain       Date:  2008-06-11       Impact factor: 13.501

10.  B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis.

Authors:  Roberta Magliozzi; Barbara Serafini; Barbara Rosicarelli; Giuseppe Chiappetta; Caterina Veroni; Richard Reynolds; Francesca Aloisi
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

View more
  18 in total

1.  Programmed Cell Death Protein 1-Positive CD8+ T Cells in Multiple Sclerosis: Exhausted Fighters or Peacekeepers.

Authors:  Joost Smolders; Jörg Hamann
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-04-22

2.  The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Authors:  Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

3.  Small molecule screening identifies inhibitors of the Epstein-Barr virus deubiquitinating enzyme, BPLF1.

Authors:  Sage L Atkins; Safiyyah Motaib; Laura C Wiser; Sharon E Hopcraft; Paul B Hardy; Julia Shackelford; Peter Foote; Ashley H Wade; Blossom Damania; Joseph S Pagano; Kenneth H Pearce; Christopher B Whitehurst
Journal:  Antiviral Res       Date:  2019-11-08       Impact factor: 5.970

Review 4.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 5.  Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.

Authors:  Jennifer C Massey; Ian J Sutton; David D F Ma; John J Moore
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

Review 6.  Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers.

Authors:  Kelen Cristina Ribeiro Malmegrim; João Rodrigues Lima-Júnior; Lucas Coelho Marlière Arruda; Júlia Teixeira Cottas de Azevedo; Gislane Lelis Vilela de Oliveira; Maria Carolina Oliveira
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

Review 7.  Epstein-Barr Virus and miRNAs: Partners in Crime in the Pathogenesis of Multiple Sclerosis?

Authors:  Asma Hassani; Gulfaraz Khan
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

Review 8.  Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders.

Authors:  Luisa F Duarte; Mónica A Farías; Diana M Álvarez; Susan M Bueno; Claudia A Riedel; Pablo A González
Journal:  Front Cell Neurosci       Date:  2019-02-26       Impact factor: 5.505

Review 9.  B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.

Authors:  Maria T Cencioni; Miriam Mattoscio; Roberta Magliozzi; Amit Bar-Or; Paolo A Muraro
Journal:  Nat Rev Neurol       Date:  2021-06-01       Impact factor: 42.937

Review 10.  Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity.

Authors:  Kristina M Harris; Tingting Lu; Noha Lim; Laurence A Turka
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.